Stockwatch: Trench warfare
This article was originally published in Scrip
As Europeans marked 70 years since the end of the war in Europe last weekend, conflict of a different sort was being waged between investors and investment bank analysts. Writers on behavioral finance typically think of conflict in the context of investors buying and selling the same stock. However, at times last week a much more malevolent force was working, one reminiscent of the way incompetent and distant general staff in the Great War ordered soldiers to their certain death from a fusillade of machine fire in the brutal European battlefields as they dressed for a regimental dinner many miles away.
You may also be interested in...
As industry bellwether J&J kicked-off 2019 fourth-quarter and full-year earnings season for life sciences companies, its financial results left investors feeling the cold. But with coronavirus envy sweeping a raft of smaller biotech companies, J&J may have the last laugh.
Stock market reaction to the first day’s news from the 38th J.P. Morgan Healthcare conference in San Francisco was negative, probably because expectations for a continuation of December’s bumper M&A bonanza were too high.
With the 38th J.P. Morgan Healthcare conference about to start in San Francisco, expectations in the investment community are naturally high. This is after a year when the NASDAQ Biotech Index approached its 2015 all-time high, fueled by the acquisitions of biotech companies by pharma companies.